Reconcile

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

флуоксетин

Available from:

Forte Healthcare Limited

ATC code:

QN06AB03

INN (International Name):

fluoxetine

Therapeutic group:

Кучета

Therapeutic area:

Psychoanaleptics

Therapeutic indications:

Като помощно средство при лечение на разделение-зависими заболявания при кучетата се проявява разрушаването и недостатъци форми на поведение (става и неуместен за изхождане и / или уриниране) и само в съчетание с поведенческа модификация техники.

Product summary:

Revision: 14

Authorization status:

упълномощен

Authorization date:

2008-07-08

Patient Information leaflet

                                15
B. ЛИСТОВКА
16
ЛИСТОВКА:
RECONCILE 8 MG ДЪВЧАЩИ ТАБЛЕТКИ ЗА КУЧЕТА
RECONCILE 16 MG ДЪВЧАЩИ ТАБЛЕТКИ ЗА КУЧЕТА
RECONCILE 32 MG ДЪВЧАЩИ ТАБЛЕТКИ ЗА КУЧЕТА
RECONCILE 64 MG ДЪВЧАЩИ ТАБЛЕТКИ ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба :
FORTE Healthcare ltd
Cougar Lane
Naul
Co. Dublin
Ireland
Производител, отговорен за
освобождаване на партидата:
Tairgi Tread -Lia Baile na Sceilge Teo T/A Ballinskelligs
Veterinary Products,
Ballinskelligs,
Co. Kerry,
V23 XR52,
Ireland
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Reconcile 8 mg дъвчащи таблетки за кучета
Reconcile 16 mg
дъвчащи таблетки за кучета
Reconcile 32 mg
дъвчащи таблетки за кучета
Reconcile 64 mg
дъвчащи таблетки за кучета
fluoxetine
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦЯ И
ЕКСЦИПИЕНТИТЕ
Всяка таблетка съдържа:
Reconcile 8
mg: fluoxetine 8 mg (еквивалентен на 9,04 mg fluoxetine
hydrochloride)
Reconcile 16 mg: fluoxetine 16 mg (еквивалентен на 18,08
mg fluoxetine hydrochloride)
Reconcile 32 mg: fluoxetine 32 mg (еквивалентен на 36,16
mg fluoxetine hydrochloride)
Reconcile 64 mg: fluoxetine 64 mg (еквивалентен на 72,34
mg fluoxetine hydrochloride)
Изпъстрена с петънца, бронзова до
кафява кръгла дъвчаща таблетка, с
релефен номер и от
двете страни (както е описано по-долу):
Reconcile 8 mg дъвчащи таблетки за кучета: 4203
Reconci
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Reconcile 8 mg дъвчащи таблетки за кучета
Reconcile 16 mg дъвчащи таблетки за кучета
Reconcile 32 mg дъвчащи таблетки за кучета
Reconcile 64 mg дъвчащи таблетки за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка таблетка съдържа:
АКТИВНА СУБСТАНЦИЯ:
Reconcile 8 mg: fluoxetine 8 mg (еквивалентно на 9,04 mg
fluoxetine hydrochloride)
Reconcile 16 mg: fluoxetine 16 mg (еквивалентно на 18,08
mg fluoxetine hydrochloride)
Reconcile 32 mg: fluoxetine 32 mg (еквивалентно на 36,16
mg fluoxetine hydrochloride)
Reconcile 64 mg: fluoxetine 64 mg (еквивалентно на 72,34
mg fluoxetine hydrochloride)
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Таблетка за дъвчене.
Изпъстрени с петънца, бронзови до
кафяви кръгли дъвчащи таблетки,
щамповани от едната
страна с номер (както са изброени
по-долу):
Reconcile 8 mg таблетки:
4203
Reconcile 16 mg таблетки:
4205
Reconcile 32 mg таблетки: 4207
Reconcile 64 mg таблетки: 4209
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
Като помощно средство при лечение на
свързани с раздяла разстройства при
кучета,
проявяващи се с разрушителност и
неуместно поведение (лай и н
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 16-06-2021
Public Assessment Report Public Assessment Report Spanish 19-10-2016
Patient Information leaflet Patient Information leaflet Czech 16-06-2021
Public Assessment Report Public Assessment Report Czech 19-10-2016
Patient Information leaflet Patient Information leaflet Danish 16-06-2021
Public Assessment Report Public Assessment Report Danish 19-10-2016
Patient Information leaflet Patient Information leaflet German 16-06-2021
Public Assessment Report Public Assessment Report German 19-10-2016
Patient Information leaflet Patient Information leaflet Estonian 16-06-2021
Public Assessment Report Public Assessment Report Estonian 19-10-2016
Patient Information leaflet Patient Information leaflet Greek 16-06-2021
Public Assessment Report Public Assessment Report Greek 19-10-2016
Patient Information leaflet Patient Information leaflet English 16-06-2021
Public Assessment Report Public Assessment Report English 19-10-2016
Patient Information leaflet Patient Information leaflet French 16-06-2021
Public Assessment Report Public Assessment Report French 19-10-2016
Patient Information leaflet Patient Information leaflet Italian 16-06-2021
Public Assessment Report Public Assessment Report Italian 19-10-2016
Patient Information leaflet Patient Information leaflet Latvian 16-06-2021
Public Assessment Report Public Assessment Report Latvian 19-10-2016
Patient Information leaflet Patient Information leaflet Lithuanian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-06-2021
Public Assessment Report Public Assessment Report Lithuanian 19-10-2016
Patient Information leaflet Patient Information leaflet Hungarian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 16-06-2021
Public Assessment Report Public Assessment Report Hungarian 19-10-2016
Patient Information leaflet Patient Information leaflet Maltese 16-06-2021
Public Assessment Report Public Assessment Report Maltese 19-10-2016
Patient Information leaflet Patient Information leaflet Dutch 16-06-2021
Public Assessment Report Public Assessment Report Dutch 19-10-2016
Patient Information leaflet Patient Information leaflet Polish 16-06-2021
Public Assessment Report Public Assessment Report Polish 19-10-2016
Patient Information leaflet Patient Information leaflet Portuguese 16-06-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 16-06-2021
Public Assessment Report Public Assessment Report Portuguese 19-10-2016
Patient Information leaflet Patient Information leaflet Romanian 16-06-2021
Public Assessment Report Public Assessment Report Romanian 19-10-2016
Patient Information leaflet Patient Information leaflet Slovak 16-06-2021
Public Assessment Report Public Assessment Report Slovak 19-10-2016
Patient Information leaflet Patient Information leaflet Slovenian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 16-06-2021
Public Assessment Report Public Assessment Report Slovenian 19-10-2016
Patient Information leaflet Patient Information leaflet Finnish 16-06-2021
Public Assessment Report Public Assessment Report Finnish 19-10-2016
Patient Information leaflet Patient Information leaflet Swedish 16-06-2021
Public Assessment Report Public Assessment Report Swedish 19-10-2016
Patient Information leaflet Patient Information leaflet Norwegian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 16-06-2021
Patient Information leaflet Patient Information leaflet Icelandic 16-06-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 16-06-2021
Patient Information leaflet Patient Information leaflet Croatian 16-06-2021
Public Assessment Report Public Assessment Report Croatian 19-10-2016

Search alerts related to this product

View documents history